Researchers Discover Waste Disposal System in the Brain

by Staff Writer
June 27, 2024 at 12:09 PM UTC

Researchers have discovered a previously unknown lymphatic-like system in the brain, highlighting its role in waste removal.

Clinical relevance: Researchers have discovered a previously unknown lymphatic-like system in the brain, called the glymphatic system, which aids in waste removal.

  • Historically, it was believed that neurovascular bundles supplying organs with nerves, arteries, veins, and lymphatic vessels didn’t include the brain.
  • The glymphatic system manages cerebrospinal fluid flow through the brain and is crucial for waste removal, with disruptions potentially contributing to diseases like Alzheimer’s.
  • Despite measurement challenges, researchers have developed MRI-based methods to indirectly assess glymphatic flow, providing potential biomarkers for early diagnosis and treatment of neurodegenerative diseases.

In a groundbreaking discovery, researchers in China have identified a previously unknown lymphatic-like system in the brain, upending conventional wisdom about brain physiology.

Historically, medical science believed that the neurovascular bundles that supply organs with nerves, arteries, veins, and lymphatic vessels operated independently of the brain.

Now new research has exposed the presence of the glymphatic system, a network that promotes the disposal of the brain’s waste products.

Decades in the Making

The long road that led to this revelation began as far back as the late 1960s when M. Földi and colleagues first described “pre-lymphatic channels” in the human brain, connecting to cervical lymph nodes.

It took another 40 years before researchers – Jeffrey Iliff and his colleagues – floated the idea of a glymphatic system in 2012. The researchers posited that this system managed the flow of cerebrospinal fluid through the brain, facilitating the removal of waste products, including synaptic vesicular debris and neuronal waste.

The research indicates that glymphatic flow, which accelerates while we sleep, plays a vital role in maintaining a healthy brain. When this flow is interrupted, waste will accumulate, potentially contributing to diseases such as Alzheimer’s, characterized by the accumulation of β-amyloid in the brain.

Measuring the Glymphatic Flow in the Brain

Despite the challenges of measuring glymphatic flow because of how slowly it works its way through brain tissue, researchers have developed an indirect approach that takes advantage of magnetic resonance imaging (MRI). These methods, including the calculation of perivascular space volume fraction (PVSVF-WM), free water (FW-WM) metrics, and the analysis along the perivascular space (ALPS) index, offer insights into the flow of the brain’s interstitial fluid.

In the latest issue of Radiology, Shiwei Lin and his colleagues focus on how obstructive sleep apnea (OSA) disrupts glymphatic flow. Researchers theorized that this disorder, which makes sleep difficult (at best), progressively affects glymphatic metrics with growing severity.

Methodology – And Hope

The study involved 105 participants with snoring issues and 50 healthy controls. Through extensive cognitive testing and MRI analysis, the researchers found a link between severe OSA and abnormal glymphatic metrics and impaired cognitive performance.

Later, a subset of participants with moderate OSA received a surgical procedure to address their symptoms. Post-surgery, these participants showed normalized glymphatic metrics and improved cognitive performance, hinting at the potential correction of glymphatic flow disruption.

While the researchers concede that further technological advancements would be required to measure glymphatic flow directly, the findings nevertheless open the door to early diagnosis and treatment of neurodegenerative diseases.

“The take-home message for radiologists is that this study provides strong evidence that relatively crude MRI measurements of glymphatic flow are probably good enough to use as biomarkers for diseases that accumulate waste products within the brain parenchyma,” John Port, MD, professor of radiology and associate professor of psychiatry at the Mayo Clinic in Rochester, Minnesota, wrote in a commentary about the research. “Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, prion disease — we definitely need biomarkers to diagnose these diseases at an earlier stage so that we can begin treatment earlier and improve outcomes.”

Further Reading

Researchers Uncover Five Different Types of Alzheimer’s

Identifying and Treating Insomnia in Patients Living With Alzheimer’s

Blood Test Offers Parkinson’s Early Warning System

Original Research

Efficacy and Safety of Ketamine/Esketamine in Bipolar Depression in a Clinical Setting

In a small sample of patients with bipolar depression treated with ketamine/esketamine, no evidence of mania or hypomania was seen during acute treatment.

Mia C. Santucci and others

Brief Report

Trend in Emergency Department Visits Among Children and Youth With Autism Spectrum Disorder: A Cross-Sectional Analysis of the National Hospital Ambulatory Medical Care Survey, 2016–2021

Approximately 38.7% of children and youth presented to the emergency department with a concurrent psychiatric diagnosis, highlighting the importance of a holistic psychiatric care approach, irrespective of the primary reason for their visit

Abid Rizvi and others